Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ZEVRA THERAPEUTICS, INC.ZVRA · Entity 5212 | Chief Scientific Officer | January 31, 2024 | February 03, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ZEVRA THERAPEUTICS, INC.
Report date January 31, 2024 · Filed February 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 79,000 |
Reported balance
After 2024-01-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-31 · Grant · Acquired 79,000 · Balance 79,000 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Grant to the Reporting Person of restricted stock units ("RSU"). F2: The restricted stock units will vest and settle as to one third of the restricted stock units on January 31, 2025, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting person's ongoing employment. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Grant to the Reporting Person of restricted stock units ("RSU").
F2: The restricted stock units will vest and settle as to one third of the restricted stock units on January 31, 2025, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting person's ongoing employment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 31, 2024 Filed Feb 3, 2024 01:13 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantRestricted Stock Unit · Derivative | 79,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-003026 · rdgdoc.xml · derivative · entry 1 Guenther Sven · CIK 0001638368 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,000 Underlying: Common Stock · 79,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Grant to the Reporting Person of restricted stock units ("RSU"). F2 · derivative.exercise_date: The restricted stock units will vest and settle as to one third of the restricted stock units on January 31, 2025, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting person's ongoing employment. F2 · derivative.expiration_date: The restricted stock units will vest and settle as to one third of the restricted stock units on January 31, 2025, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting person's ongoing employment. Read SEC document |
| January 09, 2023 Filed Jan 12, 2023 02:50 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 306,000 | $0.00 Strike: $4.54 | $0.00 |
DisclosureSEC source: 0001437749-23-000916 · rdgdoc.xml · derivative · entry 1 Guenther Sven · CIK 0001638368 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,000 Underlying: Common Stock · 306,000 shares Expires 2033-01-08 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan (the "Plan"). 25% of the shares will vest on January 6, 2024 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 22:17 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 83,486 | $0.00 Strike: $7.17 | $0.00 |
DisclosureSEC source: 0001437749-22-002400 · rdgdoc.xml · derivative · entry 1 Guenther Sven · CIK 0001638368 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,486 Underlying: Common Stock · 83,486 shares Expires 2032-01-31 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan (the "Plan"). 25% of the shares will vest on February 1, 2023 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| August 20, 2021 Filed Aug 24, 2021 20:26 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 81,716 | $0.00 Strike: $9.06 | $0.00 |
DisclosureSEC source: 0001437749-21-020858 · rdgdoc.xml · derivative · entry 1 Guenther Sven · CIK 0001638368 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,716 Underlying: Common Stock · 81,716 shares Expires 2031-08-19 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan (the "Plan"). 25% of the shares will vest on August 20, 2022 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| February 05, 2020 Filed Feb 8, 2020 02:39 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 160,000 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001437749-20-002100 · rdgdoc.xml · derivative · entry 1 Guenther Sven · CIK 0001638368 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2030-02-04 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2014 Equity Incentive Plan (the "Plan"). 50% of the shares underlying the option will vest upon the approval by the U.S. Food and Drug Administration of a new drug application for the Company's product candidate, KP415. The remaining 50% of the shares underlying the option will vest upon the approval of a label for KP415 which includes 30 minute onset and 13-hour duration (the "30/13 Label") as defined in the KP415 License Agreement dated September 3, 2019. Each vesting event is contingent upon such optionee's continued employment with the Issuer at the relevant vesting date as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 21:15 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 56,000 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001437749-19-023646 · rdgdoc.xml · derivative · entry 1 Guenther Sven · CIK 0001638368 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,000 Underlying: Common Stock · 56,000 shares Expires 2029-11-24 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2014 Equity Incentive Plan (the "Plan"). 100% of the shares underlying the option will vest upon the acceptance of a new drug application for the Company's product candidate, KP415, by the U.S. Food and Drug Administration, provided that at the relevant vesting date such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| February 06, 2019 Filed Feb 9, 2019 00:28 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 160,000 | $0.00 Strike: $2.66 | $0.00 |
DisclosureSEC source: 0001437749-19-002180 · rdgdoc.xml · derivative · entry 1 Guenther Sven · CIK 0001638368 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2029-02-05 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2014 Equity Incentive Plan (the "Plan"). 25% of the shares will vest on February 6, 2020 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| January 25, 2018 Filed Jan 29, 2018 23:56 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001437749-18-001306 · rdgdoc.xml · derivative · entry 1 Guenther Sven · CIK 0001638368 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-01-24 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2014 Equity Incentive Plan (the "Plan"). 25% of the shares will vest on January 25, 2019 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 22:04 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $3.55 | $0.00 |
DisclosureSEC source: 0001437749-17-001393 · rdgdoc.xml · derivative · entry 1 Guenther Sven · CIK 0001638368 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-01-26 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2014 Equity Incentive Plan (the "Plan"). 25% of the shares will vest on January 27, 2018 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.